AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Optomed Oyj

Report Publication Announcement Aug 4, 2023

3329_fs_2023-08-04_d9c426cd-a99b-4957-b470-80f4106bee3c.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Disclosure 435815

Optomed Oyj - Financial Calendar

Optomed's financial reporting in 2024

Optomed PlcStock Exchange Release4 August 2023 at 9.05, Helsinki Optomed's financial reporting in 2024 Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and Interim Reports in 2024 as follows: · Financial Statement Bulletin for 1 January - 31 December 2023, 15 February 2024 · Interim Report for 1 January - 31 March 2024, 7 May 2024 · Half-Year Financial Report for 1 January - 30 June 2024, 8 August 2024 · Interim Report for 1 January - 30 September 2024, 7 November 2024 Annual Report 2023, which includes the company's financial statements, the report of the Board of Directors, the corporate governance statement and the remuneration report, will be published during the week starting on 26 February 2024 at the latest. Optomed's Annual General Meeting is planned to be held on 10 May 2024 in the Helsinki region, Finland. The Board of Directors will convene the meeting separately at a later date. A shareholder who requests a certain issue belonging to the General Meeting to be included on the agenda of the meeting, is asked to notify the Board of Directors in writing by post Optomed Plc, Yrttipellontie 1, FI-90230 Oulu, Finland no later than 14 March 2024. Optomed Plc Further enquiries Sakari Knuutti, CFO, Optomed Plc, [email protected] Optomed in Brief Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 55 international patents protecting the technology. www.optomed.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.